Reversible conduction failure in acute inflammatory demyelinating polyneuropathy

• Published in: Scientific reports Vol. 12; no. 1; p. 18562
• Main Authors: Kim, Sooyoung, Lee, Eun Kyoung, Sohn, Eunhee
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.11.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308; 692/617; Amantadine; Demyelination; Gangliosides; Guillain-Barre syndrome; Guillain-Barre Syndrome - diagnosis; Heart Rate; Humanities and Social Sciences; Humans; Inflammation; multidisciplinary; Neural Conduction; Neuropathy; Patients; Polyneuropathy; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-19547-0

Reversible conduction failure (RCF) has been documented in acute motor axonal neuropathy (AMAN) and is considered a sign of nodopathy. Several reports of RCF in acute inflammatory demyelinating polyneuropathy (AIDP) have suggested that it could be a manifestation of nodopathy. We conducted this study to determine the frequency of RCF in AMAN and AIDP and to compare the clinical features between the two groups with or without RCF. RCF was observed in 38.9% and 18.5% patients in the AMAN and AIDP groups in our study, respectively. AIDP patients with anti-ganglioside antibodies represented 29.4% of the cohort. The clinical features of AIDP with RCF were more similar to those of AMAN with RCF than to those of typical AIDP. However, there were no significant differences in the frequency of anti-ganglioside antibody status between the groups. AIDP with RCF may be a manifestation of nodopathy. The current dichotomous electrodiagnostic criteria, classifying demyelinating and axonal neuropathy, are insufficient to define nodopathy. Further studies are required to revise the electrodiagnostic criteria for Guillain–Barré syndrome.